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Metaplastic breast carcinomas are basal-like tumours
Aims: Recently, an immunohistochemical panel com-
prising antibodies against HER2, oestrogen receptor
(ER), epidermal growth factor receptor (EGFR) and
cytokeratin (CK) 5 ⁄ 6 was reported to identify basal-like
breast carcinomas, as defined by cDNA microarrays.
Our aim was to analyse a series of metaplastic breast
carcinomas (MBCs) using this panel plus two other
basal markers (CK14 and p63) and progesterone
receptor (PR), to define how frequently MBCs show a
basal-like immunophenotype.
Methods and results: Sixty-five cases were retrieved
from the pathology archives of the authors’ institutions
and reviewed by three of the authors. Immunohisto-
chemistry with antibodies for HER2, ER, EGFR, CK5 ⁄ 6,
CK14 and p63 was performed according to standard
methods. All but six cases (91%) showed the typical
immunoprofile of basal-like tumours (ER– and HER2–,
EGFR+ and ⁄ or CK5 ⁄ 6+). When CK14 and p63 were
added to the panel, two additional cases could be
classified as basal-like. The majority of MBCs lacked
PR, except 4 ⁄ 19 (21%) carcinomas with squamous
metaplasia.
Conclusions: Our results demonstrate that MBCs
show a basal-like phenotype, regardless of the type
of metaplastic elements. Moreover, as these neo-
plasms frequently overexpress EGFR (57%), patients
with MBC may benefit from treatment with anti-EGFR
drugs.
Keywords: carcinosarcoma, epidermal growth factor receptor (HER1), immunohistochemistry, myoepithelial,
sarcomatoid carcinoma
Abbreviations: CK, cytokeratin; EGFR, epidermal growth factor receptor; ER, oestrogen receptor; MBC, metaplastic
breast carcinoma; PR, progesterone receptor
Introduction
cDNA microarray studies are reshaping breast cancer
taxonomy. It has been demonstrated that breast
cancers can be classified according to their gene
expression profiles into four main groups: basal-like,
luminal (A and B), HER2+ and normal breast-like
breast carcinomas.1–6 Most importantly, these groups
have prognostic and predictive implications.1–3,5–8
Tumours classified into the basal-like and HER2 groups
are reported to have a more aggressive clinical beha-
viour when compared with carcinomas with luminal
and normal breast-like phenotypes.1–3,5,6
Recently, Nielsen et al.5 proposed an immunohisto-
chemical panel, comprising oestrogen receptor (ER),
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epidermal growth factor receptor (EGFR), HER2 and
cytokeratin (CK) 5 ⁄ 6, which could be used to identify
breast carcinomas with a basal-like phenotype as
defined by cDNA microarrays (Table 1). Out of 21
basal-like breast carcinomas by cDNA profiling, 16
were ER– and HER2– and EGFR+ and ⁄ or CK5 ⁄ 6+,
conferring a sensitivity of 76% and a specificity of
100%.5
In a preliminary study to characterize the morpho-
logical features of basal-like breast carcinomas,9 we
observed that areas of focal metaplastic change in
grade III invasive ductal carcinomas, in the form of
spindle and squamous cells, were independent predic-
tors of a basal-like phenotype.
Metaplastic breast carcinoma (MBC) is a descriptive
term that refers to a heterogeneous group of tumours
characterized by an intimate admixture of adeno-
carcinoma (i.e. usual types of breast cancer) with
metaplastic elements, which can be homologous
(squamous or spindle metaplasia) or heterologous
(chondroid, osseous or lipomatous differentiation).10–16
These tumours account for < 1–3.7% of all breast
carcinomas, depending on the definition and the type
of metaplasia.10–16 Based upon the immunohisto-
chemical profile and ultrastructural features of MBCs,
we17–20 and others10,12,21–23 have suggested that
these tumours show features of myoepithelial differ-
entiation. However, to the best of our knowledge,
a systematic assessment of a large series of MBCs
encompassing tumours with homologous and hetero-
logous elements, with the immunohistochemical
panel designed to identify basal-like carcinomas, has
never been performed. Here we report an analysis
of a large series of MBCs for the expression of ER,
HER2, EGFR and CK5 ⁄ 6. In addition, we also
analysed the distribution of progesterone receptor
(PR) and two other basal ⁄ myoepithelial markers
(CK14 and p63) in these neoplasms.
Materials and methods
case selection
Cases of MBC were retrieved from the pathology files
of The Royal Marsden Hospital (London, UK), The
Norwegian Radium Hospital (Montebello, Norway),
Institute of Molecular Pathology and Immunology,
University of Porto (Porto, Portugal) (IPATIMUP) and
Laborato´rio Saloma˜o & Zoppi (Sa˜o Paulo, Brazil). This
project was approved by the Local Ethics Committees.
All cases were initially reviewed by the contributing
authors, who performed additional immunohistochem-
ical markers for corroborating the diagnosis.
The cases were centrally reviewed by three of the
authors (J.S.R-F., F.M. and F.C.S.) on a multiheaded
microscope and classified into four categories according
to the criteria proposed by Huvos et al.15 and Wargotz
and Norris.10–14 Briefly, tumours were classified as
matrix producing breast carcinomas if chondroid
and ⁄ or osseous matrix was observed in the absence
of spindle and osteoclast, i.e. giant cell components.12
Neoplasms were classified as spindle cell carcinomas if
intraductal or infiltrating ductal or squamous carcin-
oma of ductal origin was contiguous to or subtly
merged with a spindle cell proliferation of neoplastic
cells, which comprised at least 50% of the tumour
bulk.10 Carcinomas with heterologous elements were
defined as tumours with an intraductal or inva-
sive carcinatomous component intimately admixed or
subtly merging with a sarcomatous spindle cell
component with evidence of chondroid, osseous or
rhabdomyoid differentiation.11,15,16 Carcinomas with
squamous differentiation were predominantly (> 50%)
or completely composed of apparent squamous cell
components admixed with areas of invasive ductal
and ⁄ or spindle cell carcinoma, in the absence of
involvement of the overlying skin.14,16 A median of
two representative blocks from each case were selected
for immunohistochemical and chromogenic in situ
hybridization analysis.
immunohistochemistry
Routinely fixed and processed, paraffin-embedded
representative tissue sections (4 lm thick) of each
case were cut and mounted on silane-coated slides.
Immunohistochemistry with antibodies for ER, PR,
EGFR, HER2, CK5 ⁄ 6, CK14 and p63 was performed
according to the streptavidin–biotin–peroxidase com-
plex or EnVision (DakoCytomation) methods as des-
cribed elsewhere.24 Clone details and antigen retrieval
methods are summarized in Table 2. Detection was
Table 1. Immunohistochemical panel for breast cancer clas-
sification as defined by Nielsen et al.
Group HER2 ER
CK5 ⁄ 6
and ⁄ or EGFR
HER2 + Any Any
Luminal – + Any
Basal-like – – +
Undetermined – – –
CK, Cytokeratin; EGFR, epidermal growth factor receptor;
ER, oestrogen receptor.
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performed with diaminobenzidine chromogen as per
routine protocol.24 Appropriate positive and negative
(omission of the primary antibody and substitution of the
primary antibody by non-immune immunoglobulin)
controls were included in each slide run. Moreover,
internal positive controls were available in the vast
majority of the cases (i.e. ER and PR, luminal cells of
adjacent ducts and acini; EGFR, CK14, CK5 ⁄ 6 and p63,
normal myoepithelial cells of adjacent ducts and acini).
Staining results were assessed by three of the authors
(J.S.R-F., F.M., F.S.C.) on a multihead microscope. A
threshold of ‡10% of positive neoplastic cells was
adopted for ER, CK5 ⁄ 6, CK14 and PR. EGFR and HER2
were scored according to the guidelines for Hercep-
test.25 Only nuclear staining was considered positive
for ER, PR and p63, whereas only cytoplasmic staining
was considered positive for CK5 ⁄ 6 and CK14. Mem-
branous staining with or without cytoplasmic staining
was regarded as specific for EGFR and HER2. A case was
considered positive for a given marker only when all
observers agreed upon its specificity and distribution.
Results
The histological classification and immunohistochem-
ical results are summarized in Table 3.
her2
All but two MBCs lacked HER2 overexpression (2+ or
3+). Both were carcinomas with squamous metaplasia.
Case 14, which showed HER2 2+, was subjected to
chromogenic in situ hybridization for HER2, which
demonstrated lack of amplification of HER2 gene
(data not shown). Therefore, this case was considered
negative.
oestrogen receptor
One spindle cell carcinoma and one carcinoma with
squamous metaplasia were positive for ER. Interest-
ingly, in case 46, the metaplastic spindle cells were
positive for ER, whereas in case 12 only the invasive
ductal component was ER+, whereas the metaplastic
squamous cells were consistently negative.
epidermal growth factor receptor
EGFR overexpression, defined as 2+ and 3+ reacti-
vity, was observed in 37 ⁄ 65 (56.9%) of all MBCs,
including 12 ⁄ 21 (57.1%) spindle cell carcinomas,
14 ⁄ 19 (73.7%) carcinomas with squamous meta-
plasia, 5 ⁄ 18 (27.8%) matrix producing breast carcin-
omas and 5 ⁄ 7 (71.4%) carcinomas with heterologous
elements.
ck5/6
Fifty-six of 65 (86.1%) MBCs were positive for CK5 ⁄ 6.
Five spindle cell carcinomas, two matrix producing
breast carcinomas and two carcinomas with hetero-
logous elements lacked CK5 ⁄ 6 expression.
ck14
Fifty-three of 65 (81.5%) MBCs displayed CK14
positivity. Five spindle cell carcinomas, four matrix
producing breast carcinomas, two carcinomas with
squamous metaplasia and two carcinomas with
heterologous elements lacked CK14 expression.
Interestingly, three cases of spindle cell carcinoma,
one matrix producing carcinoma and one carcin-
oma with heterologous elements lacked both CK5 ⁄ 6
Table 2. Antibodies and antigen retrieval methods
Antibody Source Clone Dilution Antigen retriveal
HER2 Dakocytomation, Glostrup, Denmark Polyclonal
(Herceptest)
Prediluted 41 min, water bath
EGFR Zymed, South San Francisco, CA, USA 31G7 1 : 50 10 min, protease
ER Dakocytomation, Glostrup, Denmark ID5 1 : 40 2 min, pressure cooker
CK5 ⁄ 6 Chemicon, Temecula, CA, USA D516B4 1 : 600 18 min, microwave oven
CK14 Novocastra, Newcastle-upon-Tyne, UK LL02 1 : 40 18 min, microwave oven
p63 Santa Cruz Biotechnology, Santa Cruz, CA, USA 4A4 1 : 200 18 min, microwave oven
PR Dakocytomation, Glostrup, Denmark PGR636 1 : 150 2 min, pressure cooker
CK, Cytokeratin; EGFR, epidermal growth factor receptor; ER, oestrogen receptor; PR, progesterone receptor.
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Table 3. Summary of immunohistochemical findings
Case Diagnosis Her2 ER EGFR CK5 ⁄ 6 CK14 p63 PR
1 Carcinoma with heterologous elements – – – + – + +
2 Carcinoma with heterologous elements – – 1+ + + + –
3 Carcinoma with heterologous elements – – 2+ – + + –
4 Carcinoma with heterologous elements – – 2+ + + + –
5 Carcinoma with heterologous elements – – 3+ – – + –
6 Carcinoma with heterologous elements – – 3+ + + + –
7 Carcinoma with heterologous elements – – 3+ + + + –
8 Carcinoma with squamous metaplasia – – – + + + +
9 Carcinoma with squamous metaplasia – – – + + – +
10 Carcinoma with squamous metaplasia – – 1+ + + – –
11 Carcinoma with squamous metaplasia 1+ – 1+ + + – –
12 Carcinoma with squamous metaplasia – + 1+ + + + +
13 Carcinoma with squamous metaplasia – – 2+ + – + –
14 Carcinoma with squamous metaplasia 2+ – 3+ + + + –
15 Carcinoma with squamous metaplasia – – 3+ + + + –
16 Carcinoma with squamous metaplasia – – 3+ + + + –
17 Carcinoma with squamous metaplasia – – 3+ + + + –
18 Carcinoma with squamous metaplasia – – 3+ + + + –
19 Carcinoma with squamous metaplasia – – 3+ + + + –
20 Carcinoma with squamous metaplasia – – 3+ + + + –
21 Carcinoma with squamous metaplasia – – 3+ + + + –
22 Carcinoma with squamous metaplasia – – 3+ + + + –
23 Carcinoma with squamous metaplasia – – 3+ + + + –
24 Carcinoma with squamous metaplasia – – 3+ + + – –
25 Carcinoma with squamous metaplasia 3+ – 3+ + + + –
26 Carcinoma with squamous metaplasia – – 3+ + – + +
27 Matrix producing carcinoma – – – – + + –
28 Matrix producing carcinoma – – – + + + –
29 Matrix producing carcinoma – – – + + + –
30 Matrix producing carcinoma – – – + + + –
31 Matrix producing carcinoma – – – + + – –
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Table 3. (Continued)
Case Diagnosis Her2 ER EGFR CK5 ⁄ 6 CK14 p63 PR
32 Matrix producing carcinoma – – – + + – –
33 Matrix producing carcinoma – – – + + – –
34 Matrix producing carcinoma – – – + + – –
35 Matrix producing carcinoma – – – + + – –
36 Matrix producing carcinoma – – 1+ – – – –
37 Matrix producing carcinoma – – 1+ + – + –
38 Matrix producing carcinoma – – 1+ + + + –
39 Matrix producing carcinoma – – 1+ + + – –
40 Matrix producing carcinoma – – 2+ + + + –
41 Matrix producing carcinoma – – 2+ + + + –
42 Matrix producing carcinoma – – 3+ + – + –
43 Matrix producing carcinoma – – 3+ + + + –
44 Matrix producing carcinoma – – 3+ + + + –
45 Spindle cell carcinoma – – – – + – –
46 Spindle cell carcinoma – + – – – + –
47 Spindle cell carcinoma – – – + + + –
48 Spindle cell carcinoma – – – + + + –
49 Spindle cell carcinoma – – – + + + –
50 Spindle cell carcinoma – – – + + + –
51 Spindle cell carcinoma – – – + + + –
52 Spindle cell carcinoma – – 1+ + + + –
53 Spindle cell carcinoma – – 1+ + + + –
54 Spindle cell carcinoma – – 2+ – – + –
55 Spindle cell carcinoma – – 2+ – – + –
56 Spindle cell carcinoma – – 2+ + + + –
57 Spindle cell carcinoma – – 3+ – – + –
58 Spindle cell carcinoma – – 3+ + – – –
59 Spindle cell carcinoma – – 3+ + + + –
60 Spindle cell carcinoma – – 3+ + + + –
61 Spindle cell carcinoma – – 3+ + + + –
62 Spindle cell carcinoma – – 3+ + + + –
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and CK14 expression. However, these cases either
expressed other keratins (CK8 ⁄ 18, CK19 or 34bE12,
data not shown) and ⁄ or were associated with high-
grade ductal carcinoma in situ.
p63
Fifty-two out of 65 (80%) MBCs showed p63 expres-
sion. In seven matrix producing breast carcinomas,
four carcinomas with squamous metaplasia and two
spindle cell carcinomas < 10% of p63+ neoplastic cells
were identified, rendering these cases negative. Inter-
estingly, all but one of the cases that lacked both
CK5 ⁄ 6 and CK14 were positive for p63. This case was
a matrix producing breast carcinoma which showed
positivity for CK8 ⁄ 18 and CK19.
progesterone receptor
Four of 19 (21.0%) carcinomas with squamous
metaplasia and one of seven (14.3%) carcinomas with
heterologous elements expressed PR, which was largely
restricted to areas with squamous metaplasia. Interest-
ingly, in cases 8 and 26, PR decorated only the non-
metaplastic elements. The remaining cases consistently
lacked PR expression.
classif ication of metaplastic breast cancer
into her2, luminal and basal-l ike groups
Following the immunohistochemical panel proposed
by Nielsen et al., 59 out of 65 MBCs (90.8%) displayed
the typical immunophenotype of basal-like breast
carcinomas (Table 4 and Figures 1, 2 and 3). Three
cases, two matrix producing breast carcinomas (cases
27 and 36) and one spindle cell carcinoma (case 45),
were negative for ER and HER2, but also lacked EGFR
and CK5 ⁄ 6 expression.
Two cases showed the immunophenotype of luminal
tumours (one carcinoma with squamous metaplasia
and one spindle cell carcinoma) and another case of
carcinoma with squamous metaplasia was classified
into the HER2 group. Interestingly, all of these cases
expressed at least one basal ⁄ myoepithelial marker.
Furthermore, one matrix producing breast carcin-
oma (case 27) and one spindle cell carcinoma (case 45)
that were both HER2–, ER–, CK5 ⁄ 6– and EGFR– were
positive for p63 and ⁄ or CK14. Hence, these cases could
be considered of basal-like phenotype if these antibodies
were included in the immunohistochemical panel for
identifying basal-like tumours.
Discussion
We have demonstrated that 90.8% of MBCs show a
basal-like immunophenotype as defined by Nielsen
et al.5 By including p63 and CK14 in the immuno-
histochemical panel, 61 out 65 (93.8%) MBCs were
classified as basal-like tumours.
In previous studies addressing clinicopathological
characteristics of basal-like carcinomas, it has been
reported that these tumours are usually of high grade,
lack well-formed ductal structures, harbour high
proliferation rates, have centrally necrotic ⁄ sclerotic
zones and show a proclivity to disseminate to the
brain and lungs, sparing regional nodes, liver and
Table 4. Classification of
65 metaplastic breast
carcinomas according to
the immunohistochemilcal
panel proposed by Nielsen
et al.
Histological type N HER2 Luminal Basal-like Undetermined
Spindle cell carcinoma 21 0 1 19 1
Carcinoma with squamous metaplasia 19 1 1 17 0
Matrix producing breast carcinoma 18 0 0 16 2
Carcinoma with heterologous elements 7 0 0 7 0
Table 3. (Continued)
Case Diagnosis Her2 ER EGFR CK5 ⁄ 6 CK14 p63 PR
63 Spindle cell carcinoma – – 3+ + + + –
64 Spindle cell carcinoma – – 3+ + + + –
65 Spindle cell carcinoma – – 3+ + + + –
CK, Cytokeratin; EGFR, epidermal growth factor receptor; ER, oestrogen receptor; PR, progesterone receptor.
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Figure 1. Spindle cell carcinoma (case 63): A, H&E; B, HER2; C, ER; D, EGFR; E, CK5 ⁄ 6; F, CK14; G, p63; H, PR.
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Figure 2. Carcinoma with squamous metaplasia (case 8): A, H&E; B, HER2; C, ER; D, EGFR; E, CK5 ⁄ 6; F, CK14; G, p63; H, PR.
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Figure 3. Carcinoma with heterologous elements (case 7): A,B, H&E; C, HER2; D, ER; E, EGFR, inset EGFR; F, CK5 ⁄ 6; G, CK14; H, p63; I, PR.
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bone.7,26–28 Recently, Jacquemier et al. demonstrated
that medullary carcinomas also show a basal-like
immunophenotype.29 Our results suggest that the
spectrum of basal-like breast carcinomas is wider than
previously appreciated and that metaplastic elements
are also features of basal-like breast cancers.
We and others have demonstrated that matrix
producing breast carcinomas, spindle cell carcinomas
and carcinomas with heterologous elements consis-
tently show features of basal ⁄ myoepithelial differenti-
ation.10,12,17–19,21,22,30,31 It has been suggested that
breast carcinomas with squamous metaplasia should
not be considered within the category of tumours with
myoepithelial differentiation.23 Although these tu-
mours consistently express basal markers (CK5 ⁄ 6,
Ck14 and p63),18,19,23,32 expression of myoid markers
is usually not found.19,23 However, there are several
lines of evidence to suggest that carcinomas with
squamous metaplasia should also be considered part of
the spectrum of tumours with basal ⁄ myoepithelial
differentiation: (i) Raju33 and Reddick et al.34 have
demonstrated a transition between myoepithelial cells
and squamous cells in benign breast lesions at histo-
logical, immunohistochemical and ultrastructural lev-
els; (ii) sorted breast myoepithelial cells, and not breast
luminal cells, undergo squamous metaplasia when
cultured in specific media;35 (iii) foci of squamous
metaplasia are frequently found in spindle cell carcin-
omas and spindle cell metaplasia is not rare in breast
carcinomas with squamous metaplasia;10,11,16,31,36,37
and (iv) matrix producing breast carcinomas and
carcinomas with heterologous elements frequently
harbour foci of squamous differentiation.12 Therefore,
the classification proposed by Leibl et al.23 in which
MBCs are grouped into (i) MBCs with squamous
differentiation and (ii) MBCs with a myoepithe-
lial immunophenotype seems to be artificial and
unjustified.
The fact that up to 93.8% of all MBCs display a basal-
like phenotype has a significant impact on our under-
standing of the biology and management of patients
diagnosed with these lesions. Basal-like breast carcin-
omas are reported to have a more aggressive clinical
behaviour and a less significant response to anthra-
cycline-based adjuvant chemotherapy than luminal and
normal-like breast carcinomas.37a Furthermore, Rou-
zier et al.38 have recently demonstrated that up to 45%
of basal-like breast carcinomas show a pathological
complete response after 12 weeks of paclitaxel followed
by four courses of neoadjuvant chemotherapy with
5-fluorouracil, doxorubicin and cyclophosphamide.38
A surprising finding in this study is that 7.7% of
MBCs showed expression of PR. Interestingly, PR
positivity was almost restricted to the metaplastic
squamous cells of the carcinoma with heterologous
elements and the four carcinomas with squamous
metaplasia. However, PR is not part of the ‘intrinsic
gene list’ used in cDNA microarray studies to classify
breast carcinomas into the five main groups.2–4,38
Although PR expression per se would not render the
classification of these tumours as basal-like invalid, it
suggests that basal-like carcinomas are not homogen-
eous. In fact, there are several lines of evidence to
suggest that basal-like carcinomas are not homogen-
eous in terms of their expression profiles6,8,29,39 and
molecular genetic features.40
Unlike the majority of invasive ductal breast carcin-
omas, MBCs are unlikely to respond to conventional
hormone therapy and anti-Her2 therapeutic schemes,
as these lesions consistently lack ER expression and
HER2 overexpression ⁄ gene amplification.41–43 In a
recent study, our group has shown that up to 25% of
MBCs harbour EGFR gene amplifications.41 Given that
there are compelling data to suggest that tumours
harbouring EGFR amplification may respond to EGFR
inhibitors,44 studies addressing the efficacy of these
agents for the treatment of patients with MBCs are
warranted.
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